Recent Company News

• 07:35 AM ET Apr 30, 2025
  

  Alphamab Oncology's pivotal phase II/III clinical trial of KN026 meets primary endpoint of PFS (HK$6.46, 0.00)

• 07:14 AM ET Apr 28, 2025
  

  CSPC Pharmaceutical Group releases 2024 ESG report (HK$6.04, 0.00)

• 08:30 AM ET Apr 25, 2025
  

  CSPC Pharmaceutical Group Limited discloses RNA drug SYH2068 injection obtains clinical trial approval (HK$6.11, 0.00)

• 08:36 AM ET Apr 22, 2025
  

  CSPC Pharmaceutical receives NMPA approval for trials of prusogliptin and metformin extended-release tablets (HK$6.05, 0.00)

• 08:29 AM ET Apr 22, 2025
  

  CSPC Pharmaceutical receives FDA approval for trials of JMT203 for cancer cachexia (HK$6.05, 0.00)

• 12:01 AM ET Apr 22, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 06:14 PM ET Apr 14, 2025
  

  CSPC Pharmaceutical Group upgraded to add from hold at CGS International (HK$5.77, 0.00)

• 05:51 AM ET Apr 14, 2025
  

  FDA approves CSPC Pharmaceutical Group's IND application for US trial of SYS6041 for advanced solid tumors (HK$5.77, 0.00)

• 06:05 AM ET Apr 11, 2025
  

  NMPA approves CSPC Pharma SYH2046 to clinical trial for treatment of heart failure after acute myocardial infarction (HK$5.27, 0.00)

• 06:09 AM ET Apr 08, 2025
  

  CSPC Pharmaceutical Group obtains NMPA clinical trial approval JMT108 for treatment of advanced malignant tumors (HK$4.89, 0.00)